Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback

 
• By Sten Stovall

Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by mixed clinical data, necessitating another Phase III trial.

MRI
Rexulti Needs Deciding Phase III Trial In Dementia-Related Agitation • Source: Shutterstock

More from Neurological

More from Therapy Areas